Sigyn Therapeutics, INC 10-Q quarterly reports

Sigyn Therapeutics is pivoting its lead therapy, Sigyn CardioDialysis, to target cardiovascular disease in ESRD patients, while reporting a reduced net loss and operating expenses for Q3 2025, despite ongoing going concern issues and increased debt.

Sigyn Therapeutics reported increased net losses and a significant cash decline in Q2 2025, raising substantial doubt about its ability to continue as a going concern, compounded by recent board and CSO resignations.

Sigyn Therapeutics reports its Q1 2025 financial results, showing a net loss but highlighting advancements in its blood purification technologies targeting infectious diseases and cancer.

Sigyn Therapeutics' Q3 2024 report details ongoing development of medical devices for cancer and infectious diseases, alongside financial results reflecting a net loss and continued investment in research and development.

Sigyn Therapeutics reports its financial results for the second quarter of 2024, highlighting ongoing research and development activities and a net loss, while also detailing its financial position and future plans.

Sigyn Therapeutics reported its first quarter 2024 results, highlighting ongoing development of its blood purification technologies and a net loss of $758,088.